Drug Type Small molecule drug  | 
Synonyms CLE-400  | 
Action agonists  | 
Mechanism H4 receptor agonists(Histamine H4 receptor agonists), SSTR4 agonists(Somatostatin receptor 4 agonists), α2A-AR agonists(Alpha-2a adrenergic receptor agonists)  | 
Active Indication  | 
Inactive Indication-  | 
Originator Organization  | 
Active Organization  | 
Inactive Organization-  | 
License Organization-  | 
Drug Highest PhasePhase 2  | 
First Approval Date-  | 
Regulation-  | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Pruritus | Phase 2 | United States   | 29 Jan 2024 | |
| Diabetic Neuropathies | Phase 1 | Israel   | 29 Sep 2022 | 





